Modality
Radioligand
MOA
GLP-1/GIP
Target
SOS1
Pathway
mTOR
MGCrohn'sSCD
Development Pipeline
Preclinical
~Sep 2009
→ ~Dec 2010
Phase 1
~Mar 2011
→ ~Jun 2012
Phase 2
~Sep 2012
→ ~Dec 2013
Phase 3
~Mar 2014
→ ~Jun 2015
NDA/BLA
~Sep 2015
→ ~Dec 2016
Approved
Mar 2017
→ Dec 2028
ApprovedCurrent
NCT03746415
2,605 pts·SCD
2018-07→TBD·Not yet recruiting
NCT07982784
1,588 pts·Crohn's
2023-04→2028-12·Recruiting
NCT08655545
467 pts·MG
2017-03→TBD·Not yet recruiting
4,660 total pts3 indications
CompletedCurrentUpcoming
Catalysts (1)
2028-12-282.7y awayPh3 Readout· Crohn's
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Not yet…
Approved
Not yet…
Approved
Recruit…
Catalysts
Ph3 Readout
2028-12-28 · 2.7y away
Crohn's
RecruitingNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03746415 | Approved | SCD | Not yet recr... | 2605 | DOR |
| NCT07982784 | Approved | Crohn's | Recruiting | 1588 | PASI75 |
| NCT08655545 | Approved | MG | Not yet recr... | 467 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 | |
| Zanurapivir | Immunocore | Phase 1 | SOS1 |